PT - JOURNAL ARTICLE AU - Freneau, Milène AU - Blanchet, Raphael AU - Benichi, Sandro AU - Mrad, Mary-Adel AU - Batta, Surya Prakash Rao AU - Rio, Marc AU - Bonnaud, Stéphanie AU - Lindenbaum, Pierre AU - Laporte, Fabien AU - Cuénot, Stéphane AU - Quillard, Thibaud AU - Morel, Sandrine AU - Kwak, Brenda R. AU - Bijlenga, Philippe AU - Deleuze, Jean-François AU - Dina, Christian AU - Bodet, Maxence AU - Chatel, Stéphanie AU - Bourcereau, Emmanuelle AU - Jouan, Solène AU - Consoli, Arturo AU - Dargazanli, Cyril AU - Ognard, Julien AU - , AU - Desal, Hubert AU - Vion, Anne-Clémence AU - Bourcier, Romain AU - Loirand, Gervaise AU - Redon, Richard TI - Identification of rare missense variants reducing cathepsin O secretion in families with intracranial aneurysm AID - 10.1101/2023.01.31.23285168 DP - 2024 Jan 01 TA - medRxiv PG - 2023.01.31.23285168 4099 - http://medrxiv.org/content/early/2024/06/06/2023.01.31.23285168.short 4100 - http://medrxiv.org/content/early/2024/06/06/2023.01.31.23285168.full AB - Intracranial aneurysm (IA) is a common cerebrovascular abnormality characterized by localized dilation and wall thinning in intracranial arteries, which can rupture and lead to fatal subarachnoid hemorrhage. Although the pathophysiology of IA remains largely unknown, increasing evidence suggests that genetic susceptibility plays a predominant role. Here, we combined whole exome sequencing and identity-by-descent analyses with functional investigations to identify rare functional variants associated to IA in families with multiple affected subjects. We identified two rare missense variants in the CTSO gene in two large pedigrees. We found that the cysteine-type papain-like cathepsin O (CTSO) encoded by CTSO is expressed in the wall of human IA domes. Stretching of vascular smooth muscle cells (VSMC) induced secretion of CTSO, which acted as an extracellular protease controlling VSMC migration and adhesion to the extracellular matrix. CTSO depletion, as well as expression of the two CTSO variants, which are poorly secreted, increased the amount of fibronectin. In addition, CTSO depletion increased VSMC stiffness, which was reduced by the addition of exogenous CTSO. Collectively, our findings identify CTSO as a potential new player in arterial remodeling, regulating fibronectin deposition and VSMC function, supporting the causal role of rare coding CTSO variants in familial forms of IA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the French national research agency (ANR) (Programme d Investissements d Avenir ANR-16-IDEX-0007 [NeXT Initiative], ANR-21-CE17-0006 [to RBo], ANR-21-CE14-0016 [to A-CV], and ANR-15-CE17-0008-01 and ANR-23-CE14-0001 [to GL]), Fondation pour la Recherche Médicale (R22131NN-RAD22168NNA to GL), Institut de France - Académie des Sciences (Lamonica Award to GL, supporting M-AM), the Inserm and Regional Council of Pays de la Loire (to RB) and the local fund Genavie (to MF and RR). Study benefited of the framework of the AneuX project supported by grants from SystemsX.ch, and evaluated by the Swiss National Science Foundation (2014/261). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards (Comite consultatif sur le traitement de l'information en matiere de recherche dans le domaine de la sante, Commission Nationale de l'Informatique et des Libertes), the Ethics Committees of Nantes, the French Ministry of Research and by the Comite de Protection des Personnes gave ethical approval for this work ((no. DC-2011-1399; Clinical Trial NCT02712892). The Geneva State Ethics Commission for Research involving humans gave ethical approval for AneuX biobank (Geneva CCER 2022-00426). The Ethics Committee on Animal Experimentation from the Region Pays de la Loire gave approval for the Animal used included in the study (approval number D44278).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data needed to support the conclusions of this study are present in the paper and/or the Supplementary Materials or are available via the corresponding authors upon reasonable request. Values for all data points are available in the Supporting Data Values file.